Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa
Productive FDA meeting paves the way for BLA submission for MCO-010 in Q1 2025 DALLAS, TX -- Oct. 10, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company develo ...
Nanoscope Therapeutics Licenses Optogenetic CatCh Technology
Innovative technology incorporated in Nanoscope's gene therapy offers hope for restoring vision in genetically caused visual impairments DALLAS, Sept. 30, 2024 -- Nanoscope Therapeutics Inc., a clinic ...
Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona
Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona DALLAS, Sept. 19, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company ...
Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona
DALLAS, Sept. 19, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy second ...
Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona
DALLAS Sept. 16, 2024 -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, and geographic atrophy today announced presentat ...
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration
Phase 3 Registrational Trial Expected to Commence in Near-termDALLAS, Sept. 12, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal ...
Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon
DALLAS, Sept. 9, 2024 -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced presentations at the Retina Soci ...
Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
DALLAS, TX -- Aug. 8, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations ( ...
Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting
DALLAS, July 10, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), ...
Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect
DALLAS, June 18, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), ...
Nanoscope Therapeutics to Present at the BIO International Convention
DALLAS, May 29, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), ...
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
DALLAS, TX (May 14, 2024) — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD ...
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress
DALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its viral ...
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress
DALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its viral ...
Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
DALLAS, May 2, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteris ...
Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits
DALLAS, April 29, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Samarendra Mohanty ...
Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor
DALLAS, April 25, 2024 -- Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. ...
Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024
DALLAS, April 17, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD) ...
Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision imp ...
Nanoscope Therapeutics Announces Participation in Upcoming Conferences
DALLAS, Feb. 21, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenera ...